The Sunday Roast
The Sunday Roast

Nov 5, 2026 · 13 min

Solvonis expands ketamine patent into behavioral addictions

S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS

The newly allowed US claims could broaden Solvonis’s commercial opportunity while the company still needs clinical evidence, regulatory progress, and financing.

3 key takeaways
  1. 1Solvonis’s new US patent claims cover ketamine-based treatments for gambling, binge eating, and other behavioral addictions.
  2. 2Anthony Tennyson links the expanded intellectual property to licensing prospects, pharmaceutical partnerships, and a potentially larger value for the 002 program.
  3. 3Near-term catalysts include trial expansion in Portugal, FDA and NIDA feedback, and progress advancing another program in the United States.

Don't miss

Anthony Tennyson says the newly covered behavioral-addiction indications could more than double the opportunity for Solvonis’s 002 asset.

The brief

Solvonis CEO Anthony Tennyson discusses newly allowed US patent claims covering ketamine-based treatments for behavioral addictions, including gambling and binge eating.

The patent may create licensing and partnership leverage, but pharmaceutical interest depends on clinical evidence, regulatory milestones, and a credible path to financing trials.

Tennyson compares the opportunity with treatment-resistant depression and Spravato, framing the expanded indications as a possible step-change for Solvonis’s 002 asset.

The episode’s practical focus is on catalysts: expanding the 001 trial into Portugal, receiving feedback on 002 and 015, and advancing 114 in the United States.

The standout claim is commercial rather than clinical: adding behavioral addictions could more than double the opportunity attached to Solvonis’s 002 program.

What was said on this episode

7 statements · 6 positive · 1 neutral

  1. Solvonis would need Phase 2 completion and Phase 3 entry to match Transcend’s deal stage.

    “We would need to complete a Phase 2 programme and be in Phase 3 to be at exactly the same stage as Transcend was”

    Listen at 3:19

  2. J&J’s Spravato has a forecast run rate above $2 billion.

    “J&J Spravato, has a run rate forecast of north of 2 billion”

    Listen at 4:18

  3. Solvonis is materially undervalued versus US psychedelic-sector peers.

    “We are materially undervalued compared to them”

    Listen at 5:27

  4. Tennyson expects progress on Solvonis programs and regulatory feedback within two to four months.

    “That is what I have confidence over in the next two to four months”

    Listen at 10:06

  5. Anthony Tennysonon S-ketamine oral thin film behavioral-addiction treatmentPositive11:09

    Behavioral-addiction treatment will likely combine oral S-ketamine film with psychosocial support.

    “it would most likely be a course of S-ketamine oral tin film in combination with either in-clinic psychosocial support or digital. psychosocial support”

    Listen at 11:09

  6. Behavioral-addiction indications more than double the market size for program 002.

    “More than doubles the market size for 002.”

    Listen at 11:25

  7. Additional behavioral indications significantly increase 002’s interest and potential partner value.

    “significantly increases the interest and the value to us and potentially to future partners of the 002 asset”

    Listen at 11:56

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.